Fritextsökning
Innehållstyper
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...
-
Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas
Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...
-
Nobelpris för kvantforskning i kirurgins tjänst
Tv-skärmar, LED-lampor – och medicinsk kirurgi – är områden som dragit nytta av forskningen som belönas med årets Nobelpris i kemi. Priset går till tre forskare...
-
Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy
Case study by ZEISS Microscopy.
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...
-
CSL Behring: Nya terapier kräver nya betalningsmodeller
DEBATT: NT-rådets beslut att inte rekommendera en genterapi för hemofili på grund av kostnad och osäker effektlängd belyser vikten av att terapier mot sällsynta...
-
Did you know that not every sphere is really a round sphere?
ZEISS Metrology Expert Tip.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...
-
The new ZEISS Celldiscoverer 7 has been launched
Adaptable automation for advanced workflows.
-
Samuel Lagercrantz: ”Geoffrey Hintons farhågor”
”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...
-
Eliceras cancerterapi utvärderas i Kina – "Bred potential"
Göteborgsbaserade Elicera Therapeutics inleder ett samarbete med ett kinesiskt universitet om utveckling av bolagets onkologiska virusterapi ELC-201.
-
Leo Pharma to cut 200 jobs and reorganize
Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.
-
Introducing ZEISS arivis Pro 4.2
Your solution for advanced image analysis and visualization.
-
Därför är SEO inte dött: “Viktigare än någonsin”
AI förändrar hur vi söker information – men grunden för att synas på nätet är densamma. För bolag inom biotech och life science är SEO särskilt viktigt: "Förtro...
-
Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy
Understand how RICS can be used to measure diffusion coefficients.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...
-
Conference recordings now available
Don't miss out on insights from leading experts.
-
Individual DNA passport could result in fewer drug side effects
You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...
-
ZEISS presents the "Quality Innovation Summit"
A global event on the future of quality assurance.
-
Fast Optical Sectioning of Developing Organisms and Tissue Microstructures
ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.
-
ZEISS Quality Innovation Summit video
An event full of experiences, talks, innovations, speeches, and state-of-the-art technology.
-
Study: Semaglutide tablet produces weight loss
The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.
-
Positiva data för vaccin i pulverform – ”Fungerar lika bra”
En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.
BREAKING